1172 / 1578
/
•
0 - 20
21 – 100
>101
Patients
Cranial
Extracranial
Antibodies
anti-EGFR / VEGF / HER2
Bevacizumab
215
201
14
Trastuzumab
7
7
0
Cetuximab
244
0
244
anti-CTLA-4
Ipilimumab
121
119
46
anti-PD-1
Nivolumab
27
27
0
Small molecules
EGFRi
Sorafenib
61
45
61
Sunitinib
76
75
62
Gefitinib/Erlotinib
71
43
48
ALKi
Crizotinib
39
15
39
BRAFi
129
128
20
MEKi
Trametinib
4
4
0
Total
994
664
534
07.09.17
ESTRO SBRT COURSE 2017 - Matthias Guckenberger
41
Kroeze
Cancer Treat Rev. 2017
Systematic review: SRT & targeted drugs
/
•
Overall, few grade IV and grade V toxicities
•
Less toxicity in brain SRS compared to SBRT
07.09.17
ESTRO SBRT COURSE 2017 - Matthias Guckenberger
42
Kroeze
Cancer Treat Rev. 2017
Systematic review: SRT & targeted drugs